ClinicalTrials.gg
CompletedNCT04353817Updated Jul 26, 2022Results posted

A Study Evaluating Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor in Subjects 6 Through 11 Years of Age With Cystic Fibrosis and F/MF Genotypes

A Phase 3 interventional study of ELX/TEZ/IVA and IVA in Cystic Fibrosis, sponsored by Vertex Pharmaceuticals Incorporated. Completed at 34 sites in 10 countries. Open to participants aged 6 Years to 11 Years. Per ClinicalTrials.gov, last updated 2022-07-26.

Sponsored by Vertex Pharmaceuticals Incorporated · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
121
Allocation
Randomized
Ages
6 Years to 11 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 23 studies testing elexacaftor in Cystic Fibrosis — 2 open to participants now, 5 under way, 2 of them phase 3. elexacaftor · Cystic Fibrosis.

Enrollment
11th of 23
121 · median 120
Started
2020
with 4 others
Phase 3
19 of 23
none open now
Registered
9th of 23
by date
Lead sponsor
20 of 23
Vertex Pharmaceuticals Incorporated

Among the 23 studies testing elexacaftor in Cystic Fibrosis, this one is the 11th largest by enrollment, is one of 5 that started in 2020, is one of 19 in phase 3, and was the 9th registered.

Cystic Fibrosis

1,621 studies on the registry are indexed under Cystic Fibrosis; 201 are open to participants now.

Browse Cystic Fibrosis studies →

Open to participants now

2 of the 23 studies testing elexacaftor in Cystic Fibrosis are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About elexacaftor

elexacaftor: first FDA approval 2019 (TRIKAFTA (COPACKAGED)), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 156 Cystic Fibrosis studies recruiting now, 95 (61%) set no upper age limit and 45 (29%) stop at 75 or younger; 86 take children under 18; 41 take healthy volunteers.

This study: 6 Years to 11 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies testing elexacaftor in Cystic Fibrosis, or all of them as a file.
02

Study summary

This study will evaluate the efficacy and safety of elexacaftor (ELX) / tezacaftor (TEZ) / ivacaftor (IVA) triple combination (TC) in subjects 6 through 11 years of age with cystic fibrosis (CF) who are heterozygous for F508del and a minimal function (MF) mutation (F/MF genotypes).

03

Conditions studied

  • Cystic Fibrosis

Browse trials for

04

Who can participate

Ages eligible
6 Years to 11 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Heterozygous for the F508del mutation (F/MF)
  • (FEV1) value greater than equal to(≥) 70%

Key Exclusion Criteria:

  • cirrhosis with or without portal hypertension
  • Lung infection with organisms associated with a more rapid decline in pulmonary status
  • Solid organ or hematological transplantation

Other protocol defined Inclusion/Exclusion criteria may apply

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
121 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Participants received placebo matched to ELX/TEZ/IVA and placebo matched to IVA in the treatment period for 24 weeks.

    Other: Placebo (matched to ELX/TEZ/IVA) · Other: Placebo (matched to IVA)

  • Experimental
    ELX/TEZ/IVA

    Participants weighing less than (\<) 30 kilograms (kg) at screening received ELX 100 mg qd/TEZ 50 mg qd/IVA 75 mg every 12 hours (q12h) and participants weighing greater than equals to (\>=) 30 kg at screening received ELX 200 mg qd/TEZ 100 mg qd/IVA 150 mg q12h in the treatment period for 24 weeks.

    Drug: ELX/TEZ/IVA · Drug: IVA

Interventions

  • DrugELX/TEZ/IVA

    Drug pages: Elexacaftor · Tezacaftor · Ivacaftor

    Fixed-dose combination tablet for oral administration qd in the morning.

    Also known as: VX-445/VX-661/VX-770, elexacaftor/tezacaftor/ivacaftor

  • DrugIVA

    Tablet for oral administration qd in the evening.

    Also known as: VX-770, ivacaftor

  • OtherPlacebo (matched to ELX/TEZ/IVA)

    Placebo matched to ELX/TEZ/IVA for oral administration once daily (qd) in the morning.

  • OtherPlacebo (matched to IVA)

    Placebo matched to IVA for oral administration qd in the evening.

06

What researchers measure

Primary outcomes

  1. Absolute Change in Lung Clearance Index 2.5 (LCI2.5)

    The LCI2.5 index is the number of lung turnovers required to reduce the end tidal inert gas concentration to 1/40th of its starting values and is calculated by dividing the sum of exhaled tidal breaths (cumulative exhaled volume (CEV)) by simultaneously measured functional residual capacity (FRC). An LCI of 7.5 and below is normal; values greater than 7.5 are abnormal. LCI is able to detect abnormalities in lung function earlier than more traditional modalities such as spirometry.

    Time frame: From Baseline Through Week 24

Secondary outcomes

  1. Absolute Change in Sweat Chloride (SwCl)

    Sweat samples were collected using an approved collection device.

    Time frame: From Baseline Through Week 24

  2. Safety and Tolerability as Assessed by Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

    Time frame: Day 1 up to Week 28

07

Results

Posted Jul 26, 2022

Participant flow

Participant flow — Overall Study
MilestonePlaceboELX/TEZ/IVA
Started6160
Completed6159
Not completed01
Withdrew: Adverse event01

Outcome measures

PrimaryAbsolute Change in Lung Clearance Index 2.5 (LCI2.5)

The LCI2.5 index is the number of lung turnovers required to reduce the end tidal inert gas concentration to 1/40th of its starting values and is calculated by dividing the sum of exhaled tidal breaths (cumulative exhaled volume (CEV)) by simultaneously measured functional residual capacity (FRC). An LCI of 7.5 and below is normal; values greater than 7.5 are abnormal. LCI is able to detect abnormalities in lung function earlier than more traditional modalities such as spirometry.

Time frame:
From Baseline Through Week 24
Reported as:
Least squares mean · index
Absolute Change in Lung Clearance Index 2.5 (LCI2.5)
indexPlaceboELX/TEZ/IVA
Absolute Change in Lung Clearance Index 2.5 (LCI2.5)-0.02 ± 0.16-2.29 ± 0.16
Statistical analysis
  • Placebo vs ELX/TEZ/IVA · Mixed-effects Model for Repeated Measure · p = <0.0001 · Least squares (ls) mean difference: -2.26 · 95% CI -2.71 to -1.81
SecondaryAbsolute Change in Sweat Chloride (SwCl)

Sweat samples were collected using an approved collection device.

Time frame:
From Baseline Through Week 24
Reported as:
Least squares mean · millimole per liter (mmol/L)
Absolute Change in Sweat Chloride (SwCl)
millimole per liter (mmol/L)PlaceboELX/TEZ/IVA
Absolute Change in Sweat Chloride (SwCl)-0.9 ± 1.5-52.1 ± 1.5
Statistical analysis
  • Placebo vs ELX/TEZ/IVA · Mixed-effects Model for Repeated Measure · p = <0.0001 (This is the nominal p-value without multiplicity controlled.) · Ls mean difference: -51.2 · 95% CI -55.3 to -47.1
SecondarySafety and Tolerability as Assessed by Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Time frame:
Day 1 up to Week 28
Reported as:
Number · participants
Safety and Tolerability as Assessed by Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
participantsPlaceboELX/TEZ/IVA
Participants With TEAEs5748
Participants With SAEs94

Adverse events

Collected over Day 1 up to Week 28. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/61 (0%)9/61 (14.8%)53/61 (86.9%)
ELX/TEZ/IVA0/60 (0%)4/60 (6.7%)46/60 (76.7%)
Most frequent serious events
Showing 10 of 11
Most frequent serious events
EventPlaceboELX/TEZ/IVA
Infective pulmonary exacerbation of cystic fibrosisInfections and infestations3/610/60
PhimosisCongenital, familial and genetic disorders0/611/60
Varicella zoster virus infectionInfections and infestations0/611/60
Bacterial test positiveInvestigations0/611/60
RashSkin and subcutaneous tissue disorders0/611/60
LymphadenitisBlood and lymphatic system disorders1/610/60
Distal intestinal obstruction syndromeGastrointestinal disorders1/610/60
IntussusceptionGastrointestinal disorders1/610/60
General physical health deteriorationGeneral disorders1/610/60
Pneumonia pseudomonalInfections and infestations1/610/60
Most frequent other events
Showing 10 of 26
Most frequent other events
EventPlaceboELX/TEZ/IVA
CoughRespiratory, thoracic and mediastinal disorders26/6114/60
HeadacheNervous system disorders12/6118/60
Abdominal painGastrointestinal disorders17/615/60
Infective pulmonary exacerbation of cystic fibrosisInfections and infestations14/611/60
Oropharyngeal painRespiratory, thoracic and mediastinal disorders12/613/60
NasopharyngitisInfections and infestations9/617/60
Productive coughRespiratory, thoracic and mediastinal disorders6/617/60
RhinorrhoeaRespiratory, thoracic and mediastinal disorders7/617/60
RashSkin and subcutaneous tissue disorders3/616/60
DiarrhoeaGastrointestinal disorders6/614/60

Baseline characteristics

Age, Continuous
Age, Continuous(years)PlaceboELX/TEZ/IVATotal
Mean9.2 ± 1.79.1 ± 1.89.2 ± 1.7
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboELX/TEZ/IVATotal
Female353570
Male262551
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboELX/TEZ/IVATotal
Hispanic or Latino011
Not Hispanic or Latino424890
Unknown or Not Reported191130
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboELX/TEZ/IVATotal
American Indian or Alaska Native011
Asian011
Native Hawaiian or Other Pacific Islander000
Black or African American011
White424587
More than one race011
Unknown or Not Reported191130
Lung Clearance Index2.5 (LCI2.5)
Lung Clearance Index2.5 (LCI2.5)(index)PlaceboELX/TEZ/IVATotal
Mean9.75 ± 1.9510.26 ± 2.2210.01 ± 2.09
08

Study locations

34 sites
  • Telethon Kids Institute
    Nedlands, Australia
  • Queensland Children's Hospital
    South Brisbane, Australia
  • The Children's Hospital at Westmead
    Westmead, Australia
  • McGill University Health Centre, Glen Site, Montreal Children's Hospital
    Montréal, Canada
  • The Hospital for Sick Children
    Toronto, Canada
  • British Columbia Children's Hospital
    Vancouver, Canada
  • Juliane Marie Center, Rigshospitalet
    Copenhagen, Denmark
  • Groupe Hospitaler Pellegrin, CHU De Bordeaux
    Bordeaux cedex, France
  • CHU Lyon - Hopital Femme Mere-Enfant
    Bron Cedex, France
  • Hopital Necker, Enfants Malades
    Paris Cedex 15, France
  • Hopital Robert Debre
    Paris, France
  • Centre de Perharidy
    Roscoff cedex, France
  • Charite Paediatric Pulmonology Department
    Berlin, Germany
  • Universitätsklinikum Essen
    Essen, Germany
  • Johann Wolfgang Goethe University
    Frankfurt, Germany
  • Justus-Liebig-Universität Gießen Zentrum fur Kinderheilkunde und Jugendmedizin
    Gießen, Germany
  • Medizinische Hochschule Hannover
    Hannover, Germany
  • Universitaetsklinikum Heidelberg, Zenter fuer Kinder-und Jugendmedizin
    Heidelberg, Germany
  • Universitaetsklinkum Koeln, CF-Studienzentrum
    Koeln, Germany
  • Hadassah University Hospital Mount Scopus
    Jerusalem, Israel
  • Schneider Children's Medical Center
    Petah Tikva, Israel
  • Universitair Medisch Centrum Groningen
    Groningen, Netherlands
  • Erasmus Medical Center / Sophia Children's Hospital
    Rotterdam, Netherlands
  • Hospital Universitari Vall d Hebron
    Barcelona, Spain
  • Hospital Virgen de la Arrixaca
    Murcia, Spain
  • Inselspital - Universitaetsspital Bern
    Bern, Switzerland
  • Kinderspital Zuerich
    Zurich, Switzerland
  • University Hospitals Bristol and Weston NHS Foundation Trust, Bristol Royal Hospital
    Bristol, United Kingdom
  • Children's Hospital of Wales
    Cardiff, United Kingdom
  • Royal Hospital for Sick Children
    Edinburgh, United Kingdom
  • Alder Hey Children's NHS Foundation Trust
    Liverpool, United Kingdom
  • Great Ormond Street Hospital for Sick Children
    London, United Kingdom
  • Royal Brompton & Harefield NHS Foundation Trust, Royal Brompton Hospital
    London, United Kingdom
  • Southampton General Hospital
    Southampton, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Details on Vertex data sharing criteria and process for requesting access can be found at: https://www.vrtx.com/independent-research/clinical-trial-data-sharing

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2020 to primary completion in May 2021, 10 months.

Results were first posted in Jul 2022, 1 year 2 months after primary completion.

Of 58 industry-sponsored phase 3 interventional studies under Cystic Fibrosis, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 36. This study's 10 months is below that.

Counting every sponsor, half of 67 studies reached it within 26 months; a quarter within 16 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 16, 2020
First posted
Apr 20, 2020
StartActual
Jun 19, 2020
Primary completionActual
May 17, 2021
CompletionActual
May 17, 2021
Results first posted
Jul 26, 2022
Last update
Jul 26, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 26, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04353817
Responsible party
Sponsor
First posted
Apr 20, 2020
Start date
Jun 19, 2020
Primary completion
May 17, 2021
Completion
May 17, 2021
Results posted
Jul 26, 2022
Last update
Jul 26, 2022

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Elexacaftor · Tezacaftor · Ivacaftor

Start the discussion